MAbs . Selection and verification of antibodies against the cytoplasmic domain of M2 of influenza, a transmembrane protein

[tetano]

MAbs


. Jan-Dec 2020;12(1):1843754.
doi: 10.1080/19420862.2020.1843754.
Selection and verification of antibodies against the cytoplasmic domain of M2 of influenza, a transmembrane protein


Nileena Velappan ¹ , Sofiya Micheva-Viteva ¹ , Samantha H Adikari ¹ , Geoffrey S Waldo ¹ , Antonietta M Lillo ¹ , Andrew R M Bradbury ²



Affiliations

• PMID: 33206590
• DOI: 10.1080/19420862.2020.1843754

Abstract

Interactions between the cytoplasmic domains of viral transmembrane proteins and host machinery often determine the outcome of viral infection. The M2 protein of influenza A has been identified as a key player in autophagy-mediated viral replication. Here, we describe the engineering and validation of an antibody specific for the cytoplasmic domain of the M2 protein. Through phage and yeast display selection techniques, we obtained an antibody that recognizes: 1) the M2 cytoplasmic domain purified from bacterial inclusion bodies and refolded, 2) full-length M2 recombinant protein expressed in mammalian cells, and 3) native M2 protein in influenza A infected cells. This antibody can serve as a molecular tool to enhance our knowledge of protein-protein interactions between influenza A virus and the host cell machinery. We anticipate the methods described herein will further the development of antibodies specific to the cytoplasmic domains of transmembrane proteins.

Keywords: Influenza A; M2 cytoplasmic domain; antibodies; antibody formats; phage display; transmembrane proteins; yeast display.